Track record · closed signal

Halozyme Therapeutics, Inc. (HALO) — closed signal from October 30, 2025

Partial Published before the outcome was known, scored automatically when the window closed on January 28, 2026.

Predicted vs. what happened

HALO price · publication thesis → realized outcomesplit-adjusted
$65.53 Published $79.95 Target $72.83 Window close $75.59 Peak
$63.00 – $66.00Entry zone — fair-value band
$65.53Published — price the day we called it
$79.95Target — the price the thesis aimed for
$75.59Peak — highest point inside the window, not a realized return
$72.83Window close — end-of-window price, context only

What happened

Partial

Reached 70% of the predicted growth at its peak, without hitting the target.

Peak price
$75.59
peak on January 7, 2026 — not a realized return
Peak gain
+15.4%
peak, from the publication price
Window close
$72.83
end-of-window price, context only
Days to target
—
Window
October 30, 2025 – January 28, 2026

The thesis — published October 30, 2025

Predicted growth
+22%
over the measurement window
Target price
$79.95
the price the thesis aimed for
Entry zone
$63.00 – $66.00
the fair-value band we waited for
Price at publication
$65.53
published October 30, 2025
Confidence
91%
how strongly the data lined up
Timeframe
Short-term (0–3 months)

Halozyme looks beaten down, but the business is healthy. A well-known research firm kept a Buy rating with a $90 target. Next week's quarterly update could beat expectations, helped by steady fees from ENHANZE partners and the new Elektrofi deal. Investor mood is improving with lots more people buying than usual. Buying a bit before results could set up a 1-3 month rebound if guidance holds.

Primary drivers

  • Price fell hard but shows early signs of turning up
  • Q3 update next week could move the stock
  • ENHANZE partner fees and the new Elektrofi agreement help
  • $90 analyst target supports confidence and helps the story

How it played out

HALO: target was not reached

Lyra published HALO at $65.53 on 2025-10-30 with a short-term thesis for 22% expected growth. The thesis pointed to a beaten-down stock starting to turn, the Q3 update next week, ENHANZE partner fees, the new Elektrofi agreement, and a $90 analyst target.

Inside the window, HALO rose but did not reach the $79.95 target. The peak was $75.59 on 2026-01-07, a 15.4% gain. It ended the window at $72.83 on 2026-01-28. The thesis partly played out because the stock rose, but it missed the stated target.

What happened during the window

On 2025-11-03, Halozyme reported better-than-expected third quarter earnings, according to Investors Business Daily. On 2026-01-28, Investors Business Daily reported that Halozyme raised its full-year 2025 sales outlook and gave 2026 revenue guidance.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Share this receipt

A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All HALO signals